Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benefit VA: Venetoclax Addition to BTKi in CLL/SLL
NCT06520098Phase 2Recruiting
- Sponsor
- VA Office of Research & Development
- Start
- Oct 2025
- Primary completion
- Jun 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by VA Office of Research & Development. Started Oct 2025; status: recruiting.
02
Drugs
venetoclax
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT06520098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06520098.